

WEDNESDAY 19th FEBRUARY 2014 COMMENCING 10.30 AM

(UNTIL 4.00 PM APPROX)

AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

- | | |
|--------------------------------|--------------|
| 1. Welcome and introduction | Enclosure |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0214 |

*To protect commercial confidentiality, the first appraisal will be conducted in private.
The final appraisal recommendation will be announced in public.*

- | | |
|---|-----------------------------------|
| 5. Appraisal 1 – Limited submission (PAS)
Tocilizumab (RoActemra[®]) in combination with methotrexate (MTX) for the treatment of juvenile idiopathic polyarthritis (rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. Tocilizumab can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. | 2/AWMSG/0214
Appendices |
|---|-----------------------------------|

The meeting will now open to the public (approx 11.15 am).

- | | |
|--|-----------------------------------|
| 6. Chairman's report (verbal update) | |
| 7. AWMSG Patient and Public Engagement Strategy | 3/AWMSG/0214 |
| 8. AWMSG Process for appraising medicines in light of negative NICE recommendation | 4/AWMSG/0214 |
| 9. AWMSG Process for considering the adoption / implementation of NICE Highly Specialised Technologies (HST) advice | 5/AWMSG/0214 |
| 10. Appraisal 2 – Full submission
Bromfenac (Yellox[®]) for treatment of postoperative ocular inflammation following cataract extraction in adults | 6/AWMSG/0214
Appendices |

- | | |
|--|--|
| 11. Appraisal 3 – Limited submission
Tenofovir disoproxil fumarate (Viread®) for the treatment of chronic hepatitis B in adults with evidence of lamivudine-resistant hepatitis B virus | 7/AWMSG/0214
Appendices |
| 12. Appraisal 4 – Limited submission
Indacaterol/glycopyrronium (Ultibro® Breezhaler®) indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease | 8/AWMSG/0214
Appendices |
| 13. National Prescribing Indicators Quarterly report – September 2013 | 9/AWMSG/0214 |
| 14. Antidotes in Wales | 10/AWMSG/0214 |

Date of next meeting:
Wednesday 2nd April 2014 in Abergavenny